Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124943643 | 12494364 | 3 | F | 20160418 | 20160718 | 20160623 | 20160727 | EXP | US-ALEXION-A201604587 | ALEXION | 47.95 | YR | M | Y | 0.00000 | 20160727 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124943643 | 12494364 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, UNK | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | |||||||
| 124943643 | 12494364 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, UNK | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | |||||||
| 124943643 | 12494364 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, UNK | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | |||||||
| 124943643 | 12494364 | 4 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, UNK | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | |||||||
| 124943643 | 12494364 | 5 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 6 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 7 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 8 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 9 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 10 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 124943643 | 12494364 | 11 | C | RITUXIMAB | RITUXIMAB | 1 | Unknown | UNK X 2 DOSE | 0 | ||||||||||
| 124943643 | 12494364 | 12 | C | RITUXIMAB | RITUXIMAB | 1 | Unknown | UNK X 1 DOSE | 0 | ||||||||||
| 124943643 | 12494364 | 13 | C | ASPIRIN /00002701/ | ASPIRIN | 1 | Unknown | 81 MG, QD | 0 | 81 | MG | QD | |||||||
| 124943643 | 12494364 | 14 | C | PHOSLO | CALCIUM ACETATE | 1 | Unknown | 667 MG, TID | 0 | 667 | MG | TID | |||||||
| 124943643 | 12494364 | 15 | C | CLONIDINE. | CLONIDINE | 1 | Unknown | 1 PATCH, QW | 0 | TRANSDERMAL PATCH | /wk | ||||||||
| 124943643 | 12494364 | 16 | C | DOCUSATE | DOCUSATE | 1 | Unknown | 100 MG, BID | 0 | 100 | MG | BID | |||||||
| 124943643 | 12494364 | 17 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Unknown | 325 MG, BID | 0 | 325 | MG | BID | |||||||
| 124943643 | 12494364 | 18 | C | LISINOPRIL. | LISINOPRIL | 1 | Unknown | 20 MG, QD | 0 | 20 | MG | QD | |||||||
| 124943643 | 12494364 | 19 | C | MELATONIN | MELATONIN | 1 | Unknown | 3 MG, BEDTIME | 0 | 3 | MG | QD | |||||||
| 124943643 | 12494364 | 20 | C | METOPROLOL. | METOPROLOL | 1 | Unknown | 100 MG, QD | 0 | 100 | MG | QD | |||||||
| 124943643 | 12494364 | 21 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | Unknown | 15 MG, BEDTIME (STRENGTH INCREASED B PCP) | 0 | 15 | MG | QD | |||||||
| 124943643 | 12494364 | 22 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 0.4 MG, PRN | 0 | .4 | MG | /yr | |||||||
| 124943643 | 12494364 | 23 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | Unknown | 4 MG, Q8H PRN | 0 | 4 | MG | Q8H | |||||||
| 124943643 | 12494364 | 24 | C | OXYCODONE | OXYCODONE | 1 | Unknown | 30 MG, Q3H, PRN | 0 | 30 | MG | Q3H | |||||||
| 124943643 | 12494364 | 25 | C | OXYCONTIN | OXYCODONE HYDROCHLORIDE | 1 | Unknown | 30 MG, BID | 0 | 30 | MG | BID | |||||||
| 124943643 | 12494364 | 26 | C | CREON | PANCRELIPASE AMYLASEPANCRELIPASE LIPASEPANCRELIPASE PROTEASE | 1 | Unknown | UNK, TID, A.C | 0 | TID | |||||||||
| 124943643 | 12494364 | 27 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Unknown | 50 MG, BEDTIME (STRENGTH INCREASED BY PCP) | 0 | 50 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124943643 | 12494364 | 1 | Haemolytic uraemic syndrome |
| 124943643 | 12494364 | 11 | Thrombotic thrombocytopenic purpura |
| 124943643 | 12494364 | 13 | Product used for unknown indication |
| 124943643 | 12494364 | 14 | Product used for unknown indication |
| 124943643 | 12494364 | 15 | Product used for unknown indication |
| 124943643 | 12494364 | 16 | Product used for unknown indication |
| 124943643 | 12494364 | 17 | Product used for unknown indication |
| 124943643 | 12494364 | 18 | Product used for unknown indication |
| 124943643 | 12494364 | 19 | Product used for unknown indication |
| 124943643 | 12494364 | 20 | Product used for unknown indication |
| 124943643 | 12494364 | 21 | Product used for unknown indication |
| 124943643 | 12494364 | 22 | Product used for unknown indication |
| 124943643 | 12494364 | 23 | Product used for unknown indication |
| 124943643 | 12494364 | 24 | Pain |
| 124943643 | 12494364 | 25 | Pain |
| 124943643 | 12494364 | 26 | Product used for unknown indication |
| 124943643 | 12494364 | 27 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124943643 | 12494364 | OT |
| 124943643 | 12494364 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124943643 | 12494364 | Asthenia | |
| 124943643 | 12494364 | Fatigue | |
| 124943643 | 12494364 | Gastrointestinal haemorrhage | |
| 124943643 | 12494364 | Haemolysis | |
| 124943643 | 12494364 | Haptoglobin decreased | |
| 124943643 | 12494364 | Infection | |
| 124943643 | 12494364 | Malaise | |
| 124943643 | 12494364 | Nausea | |
| 124943643 | 12494364 | Pain | |
| 124943643 | 12494364 | Peptic ulcer | |
| 124943643 | 12494364 | Thrombosis | |
| 124943643 | 12494364 | Underweight | |
| 124943643 | 12494364 | Urinary tract infection | |
| 124943643 | 12494364 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124943643 | 12494364 | 1 | 20151222 | 0 | ||
| 124943643 | 12494364 | 2 | 20151229 | 0 | ||
| 124943643 | 12494364 | 3 | 20160112 | 0 | ||
| 124943643 | 12494364 | 4 | 20160119 | 0 | ||
| 124943643 | 12494364 | 5 | 20160202 | 0 | ||
| 124943643 | 12494364 | 6 | 20160214 | 0 | ||
| 124943643 | 12494364 | 7 | 20160314 | 0 | ||
| 124943643 | 12494364 | 8 | 20160418 | 0 | ||
| 124943643 | 12494364 | 9 | 20160502 | 0 | ||
| 124943643 | 12494364 | 10 | 20160627 | 0 | ||
| 124943643 | 12494364 | 11 | 201406 | 0 | ||
| 124943643 | 12494364 | 12 | 201509 | 0 |